56. Nat Commun. 2018 Jul 24;9(1):2897. doi: 10.1038/s41467-018-05220-6.Targeting stromal remodeling and cancer stem cell plasticity overcomeschemoresistance in triple negative breast cancer.Cazet AS(1)(2)(3), Hui MN(1)(2)(4)(5), Elsworth BL(6), Wu SZ(1)(2)(3), RodenD(1)(2)(3), Chan CL(1)(2), Skhinas JN(1)(2), Collot R(1)(2), Yang J(1)(2), HarveyK(1)(2), Johan MZ(7)(8), Cooper C(9), Nair R(10), Herrmann D(1)(2)(3), McFarland A(1)(2), Deng N(1)(2)(3), Ruiz-Borrego M(11), Rojo F(12), Trigo JM(13), BezaresS(14), Caballero R(14), Lim E(1)(2)(3)(15), Timpson P(1)(2)(3), O'TooleS(1)(2)(5), Watkins DN(1)(2)(3)(15), Cox TR(1)(2)(3), Samuel MS(7)(8), MartínM(16), Swarbrick A(17)(18)(19).Author information: (1)Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.(2)The Kinghorn Cancer Centre, Darlinghurst, NSW, 2010, Australia.(3)St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst, NSW, 2010, Australia.(4)The Chris O' Brien Lifehouse, Camperdown, NSW, 2050, Australia.(5)Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.(6)MRC Integrative Epidemiology Unit, University of Bristol, Oakfield House,Bristol, BS8 2BN, UK.(7)Centre for Cancer Biology, SA Pathology and the University of South Australia,Adelaide, SA, 5000, Australia.(8)Faculty of Health Sciences, School of Medicine, University of Adelaide,Adelaide, SA, 5000, Australia.(9)Pathology Queensland and School of Medicine, University of Queensland, StLucia, QLD, 4006, Australia.(10)Rajiv Gandhi Centre for Biotechnology, Thycaud Post, Poojappura,Thiruvananthapuram, Kerala, 695014, India.(11)Department of Medical Oncology, Hospital Universitario Virgen del Rocío,41013, Sevilla, Spain.(12)Department of Pathology, Hospital Universitario Fundación Jiménez Díaz,28040, Madrid, Spain.(13)Department of Medical Oncology, Hospital Clínico Universitario Virgen de laVictoria, IBIMA, 29010, Málaga, Spain.(14)GEICAM, Spanish Breast Cancer Group, Madrid, 28703, Spain.(15)St Vincent's Hospital, 2010, Darlinghurst, NSW, Australia.(16)Department of Medical Oncology, Instituto de Investigación Sanitaria GregorioMarañón, Universidad Complutense, Centro de Investigación Biomédica en Red deOncología, CIBERONC-ISCIII, 28040, Madrid, Spain.(17)Garvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.a.swarbrick@garvan.org.au.(18)The Kinghorn Cancer Centre, Darlinghurst, NSW, 2010, Australia.a.swarbrick@garvan.org.au.(19)St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Darlinghurst,NSW, 2010, Australia. a.swarbrick@garvan.org.au.The cellular and molecular basis of stromal cell recruitment, activation andcrosstalk in carcinomas is poorly understood, limiting the development oftargeted anti-stromal therapies. In mouse models of triple negative breast cancer(TNBC), Hedgehog ligand produced by neoplastic cells reprograms cancer-associatedfibroblasts (CAFs) to provide a supportive niche for the acquisition of achemo-resistant, cancer stem cell (CSC) phenotype via FGF5 expression andproduction of fibrillar collagen. Stromal treatment of patient-derived xenograftswith smoothened inhibitors (SMOi) downregulates CSC markers expression andsensitizes tumors to docetaxel, leading to markedly improved survival and reducedmetastatic burden. In the phase I clinical trial EDALINE, 3 of 12 patients withmetastatic TNBC derived clinical benefit from combination therapy with the SMOiSonidegib and docetaxel chemotherapy, with one patient experiencing a completeresponse. These studies identify Hedgehog signaling to CAFs as a novel mediatorof CSC plasticity and an exciting new therapeutic target in TNBC.DOI: 10.1038/s41467-018-05220-6 PMCID: PMC6057940PMID: 30042390 